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Abstract
Background: The ability to identify patients at risk for developing preeclampsia is important for preventing
morbidity and mortality in both the mother and child. Although CYFRA 21–1 (a fragment of Cytokeratin 19)
is considered a promising biomarker for diagnosing preeclampsia, little is known regarding the levels of
CYFRA 21–1 during pregnancy. Here, we measured serum CYFRA 21–1 levels in women with an uneventful
pregnancy and in women whose pregnancy was complicated by preeclampsia. Furthermore we evaluated
whether maternal CYFRA 21–1 levels can be used to predict and/or diagnose preeclampsia.
Methods: Longitudinal, sequential blood samples were collected prospectively at seven predetermined visits
during pregnancy. Maternal CYFRA 21–1 levels were measured in 50 women with an uneventful pregnancy
(control group) and in 10 asymptomatic women whose pregnancy was later complicated by preeclampsia
(PE_long group). In addition, CYFRA 21–1 levels were measured from a single sample collected from a
separate group of 50 pregnant women with symptomatic preeclampsia (PE_state group).
Results: The CYFRA 21–1 levels were significantly higher in the PE_state group compared to the control
group (p < 0.001). In the PE_long group, CYFRA 21–1 levels were lower from gestational week 11 through
17, but were higher than the control group from gestational weeks 18 through 36.
Out of the ROC curves that were calculated to investigate the predictive and diagnostic properties of CYFRA
21–1 levels for preeclampsia, the ROC curve for diagnosing preeclampsia in gestational week 28–32 showed
the largest AUC of 0.92, at a cut-off point of 3.1 ng/ml, leading to sensitivity of 92 % and specificity of 80 %.
Conclusions: The elevated serum levels of CYFRA 21–1 observed in both groups of women with preeclampsia may
reflect endothelial damage and/or dysfunction. Our results suggest that maternal serum CYFRA 21–1 is a promising
biomarker for diagnosing preeclampsia. Although its value for predicting the long-term occurrence of subsequent
preeclampsia may be limited, our findings indicate a trend towards elevated maternal CYFRA 21–1 levels preceding
the short-term occurrence of preeclampsia in asymptomatic women. Additional prospective longitudinal studies are
needed in order to determine the value of measuring maternal serum CYFRA 21–1 in predicting preeclampsia.
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Background
Preeclampsia (PE) is a leading cause of perinatal maternal
and neonatal morbidity and mortality, affecting 2–8 % of
pregnancies in the industrialized world [1, 2]. Although
PE places high burden on both the mother and the
newborn infant, and despite considerable research over
the past few decades, the precise cause and pathophy-
siology of PE remain largely unknown. The current
leading hypothesis is that a defect in early placentation
combines with impaired trophoblast differentiation, lead-
ing to multi-stage pathogenesis [3, 4].
The initial stage of the disease, which is largely asymp-
tomatic, involves abnormal placentation, which leads
to placental ischemia. This placental stage of PE is
followed by widespread endothelial damage and dysfunc-
tion (known as the maternal stage) mediated by soluble
factors from the placenta entering the maternal circula-
tion. Given the high complexity of the disease, screening
for PE and establishing a clear diagnosis of PE remain
challenging in clinical practice. Nevertheless, the ability to
identify patients at risk for PE and the ability to accurately
diagnose patients with PE are essential in order to prevent
PE-associated morbidity and mortality.
Cytokeratin 19 is a member of the keratin family of
intermediate filament proteins responsible for maintain-
ing the structural integrity of epithelial cells [5]. Cytoker-
atin 19 and other keratins are often used to differentiate
cells of epithelial origin from hematopoietic cells in tests
that evaluate circulating tumor cells in peripheral blood
or trophoblastic particles in maternal circulation [6, 7].
When they occur in the peripheral circulation, cytokera-
tins are present primarily as partially degraded, individual
protein fragments or complexes. Cytokeratin fragment
21–1 (CYFRA 21–1), a fragment produced from Cytoke-
ratin 19, has been studied in patients with lung, esopha-
geal, and gynecological cancers and has been shown to be
a clinically useful prognostic marker [8–13]. Cytokeratins
and their fragments are released into the circulation via
several mechanisms, including cellular apoptosis, necrosis,
abnormal mitosis, and/or spillover from proliferating cells,
and these cellular mechanisms are also present in patients
with PE [14–17].
Our group and others have reported increased levels
of CYFRA 21–1 in the serum of preeclamptic women
as well as in umbilical cord blood harvested from pre-
eclamptic women [18–21]. Furthermore, serum CYFRA
21–1 levels have associated with disease severity and
appear to be unaffected by antihypertensive medications
[19, 20]. However, little is known regarding the dynamics
of CYFRA 21–1 during pregnancy, regardless of whether
the pregnancy is uneventful or complicated by PE. Given
that the placental stage of PE precedes the maternal stage,
we hypothesized that the pathogenic mechanisms of
PE lead to increased levels of CYFRA 21–1, and this
increase may precede the onset of PE-associated symp-
toms, thereby providing a marker that could be used
to predict the risk of developing PE and/or to diagnose
PE at an early stage.
To test this hypothesis, we measured CYFRA 21–1
levels in serum collected from women who had an
uneventful pregnancy and from women who subsequently
developed PE. Lastly, we examined the value of using
CYFRA 21–1 to predict and/or diagnose PE.
Methods
Study design
For this single-center, nested case-control study, biological
samples and medical data were obtained from the Biobank
for Pregnancies at the Department of Obstetrics and
Feto-maternal Medicine, Medical University of Vienna,
Vienna General Hospital. This Biobank consists of an
electronic database of clinical, sonographic, demographic,
and pregnancy outcome data, as well as maternal serum,
plasma, and urine samples. The presence of infectious
disease and maternal age under 18 years are the only
criteria for exclusion from the Biobank. At the time of
inclusion, written informed consent is obtained, and
each participant is interviewed in order to obtain a
detailed patient medical history. The design of the Biobank
includes a longitudinal arm and a state-of-disease arm.
For the longitudinal arm, all patients who are receiving
prenatal care at our department are invited to participate.
During their pregnancy, the participants are seen in
gestational week 11–13 (visit 1), gestational week 14–17
(visit 2), gestational week 18–22 (visit 3), gestational week
23–27 (visit 4), gestational week 28–32 (visit 5), gesta-
tional week 33–36 (visit 6), and after gestational week 37
(visit 7). Each visit includes a medical history assessment,
an ultrasound examination, blood sample collection, and
a physical examination. After delivery, a final outcome
regarding the relevant diagnosis is established for each
pregnancy (e.g.,. PE is defined as the final outcome if
the participant experienced PE).
In the state-of-disease arm, the participant’s blood
samples and data are collected only once (when the
pregnancy-related complication is first diagnosed). The
participants in the state-of-disease arm are women with
an established diagnosis of a pregnancy-related compli-
cation who were not included in the longitudinal arm of
the Biobank (e.g., patients who received prenatal care at
another hospital and were transferred to our hospital
due to a suspicion of PE).
Study groups
After we excluded participants in the Biobank who
presented with malignancy, multiple pregnancy, preexis-
ting hypertension and/or proteinuria, chronic renal dis-
ease, type 1 or type 2 diabetes, Crohn’s disease, ulcerative
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colitis, and/or autoimmune disease, the remaining parti-
cipants were used to create three study groups. The first
group included women participating in the longitudinal
arm with the final outcome of an uneventful pregnancy
(the control group). The second group included women
in the longitudinal arm with the final outcome of PE
(PE_long). The third group included women with pre-
eclampsia in the state-of-disease arm (PE_state). For
the control group, longitudinal serum samples were
collected at random from 50 participants with an unevent-
ful pregnancy; we excluded participants with fewer than
four of the seven Biobank visits. Pregnancy was defined
as uneventful if the participant was normotensive,
normoglycemic, had no signs of proteinuria, and delivered
a term infant (i.e., at 37 + 0 weeks of gestation or later)
that was appropriate size for the gestational age. For
the PE_long group, all eligible pregnancies from the
longitudinal arm of the Biobank with the final outcome
of PE were included (n = 10 participants). It is important
to note that in this group, samples were obtained only
before the participant developed PE; as soon as PE was
diagnosed, delivery was initiated and further blood sam-
ples could not be collected. Only one post-diagnosis
sample was obtained from one participant in this group;
this sample was excluded from analysis. Therefore, in
order to analyze samples from women with PE, we
created a study group consisting of samples obtained
from symptomatic women with PE; for this group, 50
cases of PE were selected at random from the state-of-
disease arm.
The diagnosis of PE was based on international guide-
lines [22, 23]. The diagnostic criteria for PE included a
new onset of both hypertension (systolic blood pressure
≥140 mmHg and/or diastolic blood pressure ≥90 mmHg)
and proteinuria (≥300 mg of protein per 24-h urine
collection, or protein to creatinine ratio ≥30 mg per
millimole) after gestational week 20; Severe PE was
defined by the presence of sustained severe hypertension
(two or more recordings of systolic pressure of ≥170 mmHg
or diastolic pressure of ≥110 mmHg), or evidence of
multisystem disorder; Early-onset PE was defined as
PE presenting before 34 + 0 weeks of gestation.
Sample analysis
Blood samples were collected immediately following a
blood pressure measurement and were separated by
centrifugation within two hours of collection. Serum
samples were stored in aliquots below −70 °C until
analysis in order to avoid interference due to repeated
freeze-thaw cycles. Serum CYFRA 21–1 was measured
using an electrochemiluminescence immunoassay (certified
IVD kit, Roche Diagnostics GmbH, Mannheim, Germany)
with a cobas e 620 module in a cobas 8000 modular
analyzer series (Roche Diagnostics GmbH). Serum (20 μl)
was incubated with two specific monoclonal antibodies
(KS 19.1 and BM 19.21) against Cytokeratin 19; these
two antibodies form a “sandwich” complex with Cytoker-
atin 19. This complex adheres to an electrode within the
measurement cell via a chemical biotin-streptavidin
interaction with magnetic microparticles. When voltage
is applied, a chemiluminescent signal is emitted from one
of the two antibodies, which is labeled with a Ruthenium
complex; this signal is then used to calculate the concen-
tration of CYFRA 21–1 using a standard reference curve.
The intra-assay coefficient of correlation was 7.1 % at
a concentration of 3 ng/ml. All samples were analyzed at
the Department of Laboratory Medicine, Medical Univer-
sity of Vienna, which operates a certified (ISO 9001:2008)
and accredited (ISO 15189:2008) quality management
system.
Statistical analysis
The time course of CYFRA 21–1 in the control group
was visualized graphically for each participant. For further
visualization, the median CYFRA 21–1 level measured
over time was estimated using locally weighted median
regression. Box plots were used to compare the distribu-
tion of CYFRA 21–1 levels between the study groups at
each visit. To formally test our primary null hypothesis
(i.e., equal mean CYFRA 21–1 levels in the control and
PE_long groups at each of the first six visits), a linear
mixed model was fit and an F-test was calculated for the
corresponding comparison. In the model, the mean
CYFRA 21–1 level is explained using a distinct combi-
nation of treatment group and visit, as well as a random
intercept term for each participant, which accounts for
the correlation of repeated observations within each par-
ticipant. Additionally, the same models were fit including
maternal age and BMI as co-variables to account for their
potential influence on CYFRA 21–1 levels. The differences
in CYFRA 21–1 among groups were again tested by F-
tests. For this adjusted model, the test aims to provide a
comparison of mean CYFRA 21–1 levels between subjects
of different groups, though with the same age and BMI.
The calculations were performed using the MIXED
Procedure in SAS, with the Kenward-Roger method
for calculating standard errors and degrees of freedom. A
similar test was performed for the analogous secondary
null hypothesis (i.e., no difference between the control
and PE_state groups at visits 4, 5, and 6). Visit 7 was not
included in these analyses, because it was reached only in
few pregnancies, rendering information from this visit
non-representative for the main analysis goal. As a next
step, receiver operating characteristics (ROC) analysis was
used to examine the value of using CYFRA 21–1 level to
predict the risk of PE. For each possible predictor, we
calculated the area under the ROC curve (AUC) and the
95 % confidence interval.
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For analyzing demographic data and secondary out-
comes, mean and standard deviation, or median and
range were calculated for metric variables and absolute
and relative frequencies were calculated for categorical
variables. Secondary outcomes were compared between
groups using an analysis of variance (ANOVA), Student’s
t-test, or Fisher’s exact test, where appropriate.
Results
Characteristics of the study groups
The demographic data and pregnancy outcome results of
the three groups are summarized in Table 1. No signifi-
cant difference was observed between the groups with
respect to gestational age at each visit (Table 2).
CYFRA 21–1 levels in the control group
First, we measured serum CYFRA 21–1 levels in the
women who had an uneventful pregnancy (control group)
in order to examine the relationship between gestational
age and serum levels. The individual and median serum
values of CYFRA 21–1 in the control group are shown in
Fig. 1.
CYFRA 21–1 levels in the PE_long group
Next, we measured the serum CYFRA 21–1 levels in the
PE_long group, which contains asymptomatic pregnant
women who developed PE later in their pregnancy. We
then performed an F-test to investigate the global diffe-
rence between the control and PE_long groups using a
mixed model that explains the mean serum levels of
CYFRA 21–1 across pregnancy, yielding a p-value of
0.080. With this analysis, the null hypothesis of equal
development of mean CYFRA 21–1 levels in both groups
could not be formally rejected at the 5 % significance
level.
As women in the PE_long group were significantly
older and had higher pre-pregnancy BMIs compared to
controls, we decided to investigate the influence of these
characteristics on CYFRA 21–1 levels and to calculate
another mixed model, which additionally included the
maternal variables age and BMI. In this adjusted model,
the effect of BMI led to an estimated average reduction
of CYFRA 21–1 by 0.05 (SE 0.024) ng/ml for each unit
increase in BMI; The influence of the co-variable age
was estimated with average reduction of 0.015 (SE 0.015)
ng/ml per one year increase in age. The analysis of the
Table 1 Patient characteristics and pregnancy outcome parameters
Total Control (1) PE_long (2) PE_state (3) p global p 1 vs 2 p 1 vs 3
n 110 50 10 50
Maternal Age 31.28 ± 6.4 29.9 ± 6 32.1 ± 6.4 32.5 ± 6.63 0,116a 0,336b 0,042b
Maternal BMI 24.99 ± 4.8 23.44 ± 3.9 27.2 ± 3.53 26.09 ± 5.38 0,006a 0,009b 0,006b
Smoking in pregnancy 0,057c 0,715c 0,040c
NO 89 (81 %) 36 (72 %) 8 (80 %) 45 (90 %)
YES 21 (19 %) 14 (28 %) 2 (20 %) 5 (10 %)
Parity 0,002c 0,406c <0.001c
0 50 (48 %) 19 (38 %) 4 (40 %) 27 (61 %)
1/2 46 (44 %) 30 (60 %) 5 (50 %) 11 (25 %)
> 2 8 (8 %) 1 (2 %) 1 (10 %) 6 (14 %)
GA at Delivery (weeks) 35.75 ± 4.84 39.59 ± 1.27 34.97 ± 4.42 32.05 ± 4.23 <0.001a 0,009b <0.001b
Mode of Delivery <0.001c <0.001c <0.001c
Caesarean section 70 (64 %) 17 (34 %) 10 (100 %) 43 (86 %)
Vaginal delivery 40 (36 %) 33 (66 %) 0 (0 %) 7 (14 %)
Neonatal birth weight (grams) 2471.23 ± 1132.82 3403.8 ± 398.16 1988.2 ± 784.89 1635.26 ± 966.85 <0.001a <0.001b <0.001b
Transfer of newborn to NICU <0.001c <0.001c <0.001c
NO 72 (65 %) 50 (100 %) 4 (40 %) 18 (36 %)
YES 38 (35 %) 0 (0 %) 6 (60 %) 32 (64 %)
Gender of newborn 0,324c 0,299c 0,840c
female 59 (54 %) 27 (54 %) 3 (30 %) 29 (58 %)
male 51 (46 %) 23 (46 %) 7 (70 %) 21 (42 %)
Categorical data are presented as the frequency and percentage (rounded). Continuous variables are expressed as the mean ± SD
GA gestational age, BMI pre-prenancy body mass index, NICU neonatal intensive care unit
aANOVA; bStudent’s t-test; cFisher’s exact test
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adjusted model yielded a significant global difference
between the control and PE_long groups (p = 0.023).
The median serum levels of CYFRA 21–1 during
the pregnancy are shown in Fig. 2a. At visit 1, the
median serum CYFRA 21–1 concentration in the PE_long
group and control group was 1.75 ng/ml (range: 1.48–
2.15 ng/ml) and 2.35 ng/ml (range: 2.1–2.77 ng/ml),
respectively (p = 0.046, analyzed using the Kruskal-Wallis
test). At visit 2, CYFRA 21–1 concentration was still lower
in the PE_long group than in the control group; however,
at visits 3, 4, 5, and 6 the levels were higher—albeit not to
the level of statistical significance—in the PE_long group
than in the control group.
CYFRA 21–1 levels in the PE_state group
Lastly, we compared serum CYFRA 21–1 levels between
the symptomatic women with PE (PE_state) and the
control group (Fig. 2b). Our analysis revealed that the
serum CYFRA 21–1 levels were higher in the PE_state
group compared to the control group (p < 0.001 for the
F-tests from both the unadjusted and the adjusted
models). In the adjusted model, the estimated effect of
BMI led to an average CYFRA 21–1 reduction of 0.034
(SE 0.034) ng/ml per unit increase in BMI; one year
Table 2 Gestational age and CYFRA 21–1 serum levels at the seven sample collection time points during pregnancy
visit Control PE_long PE_state Total
1 n 50 8 0 58
GA 12.14 (11.75–12.68) 12.43 (12.32–13.04) 12.14 (11.86–12.71)
CYFRA 2.35 (2.1–2.77) 1.75 (1.48–2.15) 2.3 (1.9–2.7)
2 n 47 9 0 56
GA 16.14 (15.36–16.79) 16.57 (16.14–17) 16.29 (15.43–16.86)
CYFRA 2.2 (1.8–2.6) 2.1 (1.8–2.6) 2.15 (1.8–2.6)
3 n 50 9 1 60
GA 20.57 (20.32–21) 20.57 (20.14–20.86) 22.86 (22.86–22.86) 20.57 (20.25–21)
CYFRA 1.9 (1.52–2.4) 2 (1.7–2.5) 3 (3–3) 1.9 (1.58–2.42)
4 n 47 8 12 67
GA 25.14 (24.71–25.93) 24.79 (24.21–25.36) 25.5 (24.96–26.93) 25 (24.71–26.07)
CYFRA 2 (1.65–2.55) 2.35 (2.18–3.43) 3.8 (2.82–4.12) 2.3 (1.85–2.9)
5 n 45 7 13 65
GA 30 (28.86–31.14) 29 (28.93–30.71) 30.14 (28.57–31.71) 30 (28.71–31.29)
CYFRA 2.3 (1.9–2.9) 2.6 (2.45–3.4) 4.7 (3.9–5.5) 2.6 (2.1–3.9)
6 n 47 6 19 72
GA 34 (33.29–35.29) 33.36 (33.07–33.64) 34.86 (33.71–35.5) 34 (33.39–35.43)
CYFRA 3.2 (2.5–3.8) 3.8 (3.3–5.12) 6 (4.55–6.85) 3.65 (2.85–5.58)
7 n 31 1 5 37
GA 37.57 (37–38.14) 37.86 (37.86–37.86) 37.29 (37–37.29) 37.43 (37–38.14)
CYFRA 3.7 (2.9–4.35) 4.3 (4.3–4.3) 4 (3.7–4.5) 3.8 (3–4.5)
GA and CYFRA values are presented as the median (interquartile range)
GA gestational age in weeks, CYFRA serum CYFRA 21–1 levels in ng/ml
Fig. 1 CYFRA 21–1 over time in uneventful pregnancies. Serum
CYFRA 21–1 concentration as a function of gestational age in
the control group of women with an uneventful pregnancy
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increase in maternal age led to an average reduction of
0.050 (SE 0.025) ng/ml.
To examine possible differences in CYFRA 21–1 levels
between subtypes of PE, the PE_state group (n = 50) was
split into the subgroups: (i) early-onset PE (n = 36
(72 %), median 4.3 ng/ml, IQR: 3.7–5.7) and late-onset
PE (n = 14 (28 %), median 5.4 ng/ml, IQR: 3.9–6.8) (ii)
severe PE (n = 43 (86 %), median 4.5 ng/ml, IQR:
3.7–6.2) and non-severe PE (n = 7 (14 %), median
4.5 ng/ml, IQR: 3.9–5.0), and (iii) PE cases associated
with (n = 23 (46 %), median 5.1 ng/ml, IQR: 3.7–6.5)
or without (n = 27 (54 %), median 4.1 ng/ml, IQR:
3.8–5.6) fetal growth restriction. Subgroup analysis revealed
no significant differences among groups (Wilcoxon test,
p = 0.206, p = 0.585, and p = 0.213, respectively).
Diagnosis of PE by measuring serum CYFRA 21–1
concentration
Next, we analyzed the predictive value of measuring
CYFRA 21–1 levels in diagnosing PE by analyzing the
ROC curves from visits 4, 5, and 6 (Fig. 3). The AUC
values, 95 % confidence intervals, and cut-off values with
the largest sum of sensitivity and specificity are shown
in Table 3.
Fig. 2 CYFRA 21–1 levels in the study groups. The median CYFRA 21–1 levels at each visit are shown in the control group and in the
PE_long (a) and PE_state (b) groups
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The results of this analysis show, that CYFRA 21–1
levels provide a clear distinction between women with
PE and unaffected pregnant controls.
Using maternal serum CYFRA 21–1 to predict subsequent
PE
Lastly, we used ROC AUC analyses to examine whether
maternal serum CYFRA 21–1 levels measured at each
visit and/or the change in CYFRA 21–1 levels between
two visits can be used to predict the subsequent occur-
rence of PE in asymptomatic woman. These results are
summarized in Table 3. The analyzed AUCs, together
with the graphical representation in Fig. 2, suggest that
CYFRA 21–1 levels at visits 4 to 6 have the potential
to provide some distinction between women who will
develop PE later in their pregnancy and women with
an uneventful pregnancy.
Applying the cut-off values of visit 4, 5, and 6 to our
cohort, women in the PE_long group are detected before
the clinical diagnosis based on symptoms of PE with a
median time interval of 9.2 weeks between prediction
and clinical diagnosis; However, due to the limited
sample size in the PE_long group, and due to the lack of
validation of our findings by an external sample or by
cross-validation, this should not be over-interpreted.
Discussion
The primary goal of this study was to measure the
dynamics of maternal serum CYFRA 21–1 levels during
uneventful pregnancy and during pregnancy complicated
by PE. Our secondary goal was to determine the value of
using maternal serum CYFRA 21–1 levels to diagnose
PE and/or predict the risk of developing PE in asymp-
tomatic women. Using samples obtained from the pro-
spective longitudinal Biobank study, which includes
sequential blood samples obtained at up to seven prede-
termined time points during pregnancy, we measured
the time course of maternal serum CYFRA 21–1 levels.
Our results revealed three major findings. First, the time
course of maternal CYFRA 21–1 levels differs between
uneventful pregnancies and pregnancies that are compli-
cated by PE. Second, serum levels of CYFRA 21–1 are
significantly higher in symptomatic women with PE
(i.e., in our PE_state group) compared to women with
an uneventful pregnancy, indicating that this circulating
protein fragment is a promising biomarker for diagnosing
PE. Lastly, the value of using maternal CYFRA 21–1 to
predict the long-term occurrence of preeclampsia appears
to be limited. However, our findings indicate a trend
towards elevated maternal CYFRA 21–1 levels preceding
the short-term occurrence of preeclampsia in asympto-
matic women.
Worldwide, preeclampsia is estimated to account for
approximately 50,000 cases of perinatal maternal death
Fig. 3 ROC curves. ROC curves showing the sensitivity and specificity
of using serum CYFRA 21–1 concentration measured in gestational
week 23–27 (a), 28–32 (b), or 33–36 (c) to preeclampsia
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each year [2, 24]. Therefore, developing a reliable tool
for identifying patients who are at risk for developing
PE is an important first step towards preventing PE
and PE-associated morbidity and mortality. However,
the diverse clinical presentation of PE and the lack of
a simple screen have hampered previous attempts to
develop such a tool. Recently, biomarkers such as soluble
fms-like tyrosine kinase 1 and placental growth factor
have been used to diagnose and/or predict the short-term
risk of PE in women with a clinical suspicion of PE
[25–27]. However, the ability to identify women with a
long-term risk for developing later in their pregnancy
would constitute a significant advance in the field of
obstetrics. A major obstacle against developing new
strategies for diagnosing and predicting PE is our relatively
limited understanding of the disease. For example, in-
adequate placental perfusion, hypoxia, and/or ischemia
are all believed to play a role in the placental release of
circulating soluble factors that can have widespread
consequences, including maternal systemic endothelial
damage and dysfunction, vasoconstriction, and end-organ
ischemia, ultimately resulting in the clinical symptoms
associated with PE [15, 28, 29]. The important role of
widespread endothelial dysfunction in PE is underscored
by the finding that applying serum obtained from pre-
eclamptic women to in vitro cultured endothelial cells
causes cytotoxicity [17, 30].
We previously studied the role of CYFRA 21–1 in PE
and found significantly higher levels of CYFRA 21–1 in
the serum of 32 preeclamptic women compared to 32
matched controls [20]. Our current results, which are
based on a larger number of cases, support this previous
finding. Here, we found that the serum levels of CYFRA
21–1 are approximately twofold higher in women with
PE compared to women with an uneventful pregnancy.
Intrigued by these findings, we hypothesized that the
increased levels of CYFRA 21–1 in women with PE
reflect endothelial damage and/or dysfunction due to
circulating factors of placental origin. Given that the
pathogenic changes responsible for the endothelial dys-
function clearly precede the resulting clinical symptoms
associated with PE, we further hypothesized that changes
in the serum concentration of CYFRA 21–1 also precede
the clinical symptoms of PE. Interestingly, our analysis
revealed lower levels of serum CYFRA 21–1 early in
pregnancy (i.e., at visits 1 and 2, corresponding to gesta-
tional week 11–13 and 14–17, respectively) in women
who subsequently developed PE compared to women
Table 3 Predictive power of maternal serum CYFRA 21–1 levels in symptomatic women with preeclampsia (PE_state) and in
asymptomatic women who later developed preeclampsia (PE_long)
Predictor AUC 95 % CI Cut-off (ng/ml) Sensitivity Specificity p-value
For existing Preeclampsia (PE_state)
CYFRA 21–1 level at visit:
4 0.85 0.68–1 3.6 0.67 0.96 <0.001
5 0.92 0.85–1 3.1 0.92 0.8 <0.001
6 0.88 0.8–0.97 3.9 0.89 0.77 <0.001
For subsequent Preeclampsia (PE_long)
CYFRA 21–1 level at visit:
1 0.28 0.02–0.53 NDa ND ND 0.088
2 0.51 0.29–0.74 2.5 0.44 0.7 0.909
3 0.54 0.3–0.77 2.8 0.22 0.9 0.785
4 0.71 0.51–0.9 2.1 0.88 0.53 0.037
5 0.70 0.55–0.86 2.4 1 0.51 0.012
6 0.69 0.48–0.9 2.7 1 0.34 0.074
CYFRA 21–1 increase between visits:
1 and 2 0.46 0.24–0.68 ND ND ND 0.724
2 and 3 0.48 0.25–0.71 ND ND ND 0.857
3 and 4 0.61 0.41–0.81 0.6 0.67 0.94 0.287
4 and 5 0.66 0.51–0.82 0.6 0.83 0.76 0.042
5 and 6 0.69 0.48–0.9 2.0 0.67 0.85 0.074
aCut-off values, sensitivity, and specificity are not provided if the AUC is <0.5
AUC area under the curve, 95 % CI 95 % confidence interval, CYFRA 21–1 Cytokeratin fragment 21–1, PE preeclampsia
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whose pregnancy remained uneventful. Nevertheless, the
dynamics of maternal serum CYFRA 21–1 levels differed
between the asymptomatic women who later developed
PE and the women who remained asymptomatic. For
example, CYFRA 21–1 levels were higher in the PE_long
group at visits 3 through 6; however, these differences
were not statistically significant.
As an influence of maternal BMI and age on CYFRA
21–1 levels cannot be ruled out, we decided to calculate
another mixed model, which additionally included the
maternal variables pre-pregnancy BMI and age as pre-
dictors. The results of this analysis suggest a link
between maternal BMI and maternal age, and levels of
CYFRA 21–1 independently of future PE risk. The
reasons underlying this link are unclear. One could
hypothesize that maternal obesity is associated with
endothelial dysfunction, abnormalities in placental angio-
genesis, or both. Interestingly, our adjusted model revealed
that the effect of elevated BMI led to a slight reduction of
CYFRA 21–1 levels, which might be explained by an in-
creased volume of distribution in women with elevated
BMI. This issue, more specifically the effect of maternal
BMI on serum angiogenic markers in pregnancy, was
already adressed by other groups [31, 32]. In a longitudinal
study, Zera et al. found associations between maternal BMI,
sFlt-1, and PlGF in pregnancies affected by placental
dysfunction and in normal pregnancies [33]. As the
exact mechanisms underlying the association between
maternal obesity and ischemic placental diseases like
PE are still a matter of speculation, (i) the association
of maternal characteristics like BMI and age with placental
dysfunction and subsequent endothelial damage, (ii) the
increased volume of distribution in obese women, and (iii)
the influence of these characteristics on serum levels of
biomarkers for PE deserve increased attention in future
studies.
We also investigated the value of using maternal
CYFRA 21–1 to predict the risk of developing PE later
in pregnancy. With respect to the long-term predictive
power of CYFRA 21–1, serum samples collected up until
gestational week 22 (i.e., visits 1, 2, and 3) revealed no
predictive power. Next, we analyzed samples obtained at
later gestational periods (i.e., visits 4, 5, and 6) in order
to evaluate the short-term predictive power of CYFRA
21–1. This analysis revealed that CYFRA 21–1 to some
extent has short-term predictive power, as the AUC of the
ROC curves for the increase in CYFRA 21–1 between two
subsequent visits increased incrementally with increasing
gestational age. We speculate that these findings may
reflect the increasing degree of endothelial damage that
occurs until the onset of visible symptoms associated with
PE. Therefore, CYFRA 21–1 is an interesting candidate
molecule for future studies investigating promising bio-
markers for predicting the short-term occurrence of PE.
We acknowledge that the relatively limited number of
patients in our study should be considered when inter-
preting the results. In particular, the small size of the
PE_long group (i.e., ten patients) yielded relatively wide
confidence intervals for the AUCs, thereby precluding
our ability to draw definitive conclusions regarding the
power of CYFRA 21–1 in predicting the subsequent
onset of PE. However, given the low prevalence of PE in
industrialized countries, it is extremely difficult to obtain
large numbers of PE cases using a prospective longitu-
dinal study design. Thus, in our study, only ten out of
461 patients who were initially recruited to the longitu-
dinal arm of our Biobank ultimately met the criteria
for being assigned to the PE_long group. Therefore,
we included an additional study group comprised of
symptomatic women with PE, thereby increasing the
strength of our study.
Another potential limitation of our study is the rela-
tively low number of samples obtained from PE cases at
visit 7 (i.e., after gestational week 37). In clinical practice,
the routine standard of care is to induce labor—or if
warranted, deliver by cesarean section—in symptomatic
women who present with either confirmed or suspected
PE at gestation week 37 or later. Therefore, even our
PE_state group (which contained 50 cases) included only
a few samples from women with generally mild cases of
PE at visit 7. This low number of samples late in gesta-
tion may explain at least part of the lack of difference in
CYFRA 21–1 levels between preeclamptic women and
control cases at term.
On the other hand, the prospective longitudinal design
of the Biobank and the strictly predefined endpoints
resulted in a well-characterized patient cohort that was
monitored closely throughout the entire pregnancy. This
robust study design enabled us to accurately measure
the dynamics of maternal CYFRA 21–1 throughout
pregnancy. In addition, because CYFRA 21–1 is also an
established marker for various types of cancer, the refe-
rence values for CYFRA 21–1 that we obtained may help
validate CYFRA 21–1 as a tumor marker in pregnant
women.
Conclusion
Increased levels of serum CYFRA 21–1 in preeclamptic
women may reflect endothelial damage and dysfunction
due to circulating factors of placental origin. By compar-
ing women whose pregnancy was complicated by PE
with women whose pregnancy was uneventful, we found
that CYFRA 21–1 is a promising biomarker for diagno-
sing PE. Although CYFRA 21–1 seems to have limited
value for predicting the long-term occurrence of pre-
eclampsia, our findings indicate that this marker may
be useful for predicting the short-term occurrence of
preeclampsia in asymptomatic women. Future prospective
Kuessel et al. BMC Pregnancy and Childbirth  (2016) 16:339 Page 9 of 11
longitudinal studies will help determine whether this
relatively simple, non-invasive test can be used to diagnose
and/or predict preeclampsia.
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